Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
PMID 24584183
In the same time period, 66.1% of patients lost at least 10% of their body weight, while 47.9% lost at least 15%
Meanwhile, Zepbound focuses on chronic weight management for those facing obesity or weight-related issues like high blood pressure or cholesterol, alongside diabetes
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
While some of this variation in results is likely attributable to the inherent variability of results between trials, some variation may be attributable to the slight differences in the patient populations between trials, where patients receiving tirzepatide in SURMOUNT-5 had a higher average waist circumference and body weight at baseline (mean [standard deviation (SD)] waist circumference 117.7 [16.1]
